Edwards Lifesciences (EW) reported $1.53 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 6.1%. EPS of $0.67 for the same period compares to $0.70 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.49 billion, representing a surprise of +2.85%. The company delivered an EPS surprise of +8.06%, with the consensus EPS estimate being $0.62.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Edwards Lifesciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Europe: $378.2 million versus $353.07 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.
- Net Sales- Outside of the United States: $642.5 million compared to the $621.76 million average estimate based on two analysts. The reported number represents a change of +12.9% year over year.
- Net Sales- United States: $889.7 million versus $865.54 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change.
- Net Sales- Japan: $95.3 million compared to the $105.11 million average estimate based on two analysts. The reported number represents a change of +9% year over year.
- Net Sales- Rest of World: $169 million versus the two-analyst average estimate of $163.59 million. The reported number represents a year-over-year change of +15.7%.
- Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies: $134.5 million versus $129.87 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +62.1% change.
- Net Sales by Product Group- Surgical Structural Heart: $266.8 million versus the seven-analyst average estimate of $259.33 million. The reported number represents a year-over-year change of +1%.
- Net Sales by Product Group- Transcatheter Aortic Valve Replacement: $1.13 billion versus $1.1 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change.
View all Key Company Metrics for Edwards Lifesciences here>>>
Shares of Edwards Lifesciences have returned -0.1% over the past month versus the Zacks S&P 500 composite's +5.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Edwards Lifesciences Corporation (EW): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
